The Pro Trump News homepage introduces 60 new headlines every day. Click here to explore.
The FDA is transitioning away from animal testing and opting for methods that are more effective and related to human health in the development of monoclonal antibody treatments and other pharmaceuticals.
The FDA states, “Requirements for animal testing can be minimized, enhanced, or potentially replaced through various methods, including AI-driven models of toxicity, cell lines, and organoid toxicity assessments in controlled lab environments (known as new approach methods or NAMS data).”
Today, the US Food and Drug Administration is prominently advancing by substituting animal testing with superior and human-aligned methodologies in the creation of monoclonal antibody therapy and other medications. This innovative strategy aims to enhance drug safety while speeding up the evaluation process. Concurrently, it decreases the reliance on animal testing, lowers research and development (R&D) expenses, and ultimately helps in reducing drug prices.
Animal testing regulations by the FDA are being refined, diminished, or possibly replaced utilizing a variety of strategies, such as AI-driven toxicity models and cell lines, along with organoid toxicity assessments in laboratory environments (identified as new approach methodologies or NAMS data). Institutions are encouraged to incorporate NAMS data in upcoming research new drug (IND) submissions as outlined in the recent roadmap. For making efficacy assessments, companies are also beginning to leverage existing real-world safety data from countries with similar regulatory frameworks, where the drug is already being evaluated in human studies.
“For an extended period, pharmaceutical producers have conducted additional animal testing for drugs utilized broadly in human settings globally. This initiative signifies a transformative shift in drug evaluation and holds the promise of expediting effective treatments for Americans while minimizing animal utilization.” Data will facilitate quicker and more reliable access to treatments for patients while reducing both R&D expenditures and drug costs.
Peta expressed gratitude to the Trump administration for this development.
They stated, “PETA extends thanks to the Trump administration for modernizing the FDA and aiding in the prevention of numerous animals being killed annually due to old-fashioned and costly clinical trials.”
A White House spokesperson emphasizes this achievement!
PETA is thankful to the Trump administration for advancing the FDA and mitigating the annual deaths of tens of thousands of animals through costly and outdated clinical testing. https://t.co/unlyynplmh
– PETA (@peta) April 14, 2025
PETA, which has criticized health officials for previous animal testing practices, including those of Dr. Anthony Fauci, reacted positively to the recent policy direction taken by the Trump administration.
“PETA commends the FDA’s decision to implement human-centered testing approaches to eliminate harmful animal testing and assess antibody therapy,” stated Kathy Guillermo, PETA’s senior vice president.
“This is a significant step toward fulfilling the agency’s promise to reduce animal utilization, a goal that PETA fervently champions. All animal testing, including ineffective vaccines and tests conducted on monkeys at federally funded primate facilities, urges the FDA to adopt more 21st-century scientific practices.”
PETA even supports one of Trump’s initiatives!
advertisement
